Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis

Peter Flatt, C. J. Bailey, B. D. Green

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The enteroinsular axis (EIA) constitutes a physiological signalling system whereby intestinal endocrine cells secrete incretin hormones following feeding that potentiate insulin secretion and contribute to the regulation of blood glucose homeostasis. The two key hormones responsible are named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent years have witnessed sustained development of antidiabetic therapies that exploit the EIA. Current clinical compounds divide neatly into two classes. One concerns analogues or mimetics of GLP-1, such as exenatide (Byetta) or liraglutide (NN2211). The other group comprises the gliptins (e. g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Ongoing research indicates that further incretin and gliptin compounds will become available for clinical use in the near future, offering comparable or improved efficacy. For incretin analogues there is the prospect of prolonged duration of action and alternative routes of administration. This review focuses on recent advances in pre-clinical research and their translation into clinical studies to provide future therapies for type 2 diabetes targeting the EIA.
LanguageEnglish
Pages125-137
JournalCurrent Drug Metabolism
Volume10
Issue number2
Publication statusPublished - Feb 2009

Fingerprint

Incretins
Drug Delivery Systems
Hypoglycemic Agents
Glucagon-Like Peptide 1
Dipeptidyl-Peptidase IV Inhibitors
Drug Therapy
Hormones
Dipeptidyl Peptidase 4
Glucose
Peptides
Endocrine Cells
Research
Type 2 Diabetes Mellitus
Blood Glucose
Homeostasis
Insulin
Enzymes
Therapeutics
Liraglutide
exenatide

Cite this

Flatt, Peter ; Bailey, C. J. ; Green, B. D. / Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis. In: Current Drug Metabolism. 2009 ; Vol. 10, No. 2. pp. 125-137.
@article{f17e3148bdfb44e6bf55f896f1ea7458,
title = "Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis",
abstract = "The enteroinsular axis (EIA) constitutes a physiological signalling system whereby intestinal endocrine cells secrete incretin hormones following feeding that potentiate insulin secretion and contribute to the regulation of blood glucose homeostasis. The two key hormones responsible are named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent years have witnessed sustained development of antidiabetic therapies that exploit the EIA. Current clinical compounds divide neatly into two classes. One concerns analogues or mimetics of GLP-1, such as exenatide (Byetta) or liraglutide (NN2211). The other group comprises the gliptins (e. g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Ongoing research indicates that further incretin and gliptin compounds will become available for clinical use in the near future, offering comparable or improved efficacy. For incretin analogues there is the prospect of prolonged duration of action and alternative routes of administration. This review focuses on recent advances in pre-clinical research and their translation into clinical studies to provide future therapies for type 2 diabetes targeting the EIA.",
author = "Peter Flatt and Bailey, {C. J.} and Green, {B. D.}",
year = "2009",
month = "2",
language = "English",
volume = "10",
pages = "125--137",
journal = "Current Drug Metabolism",
issn = "1389-2002",
number = "2",

}

Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis. / Flatt, Peter; Bailey, C. J.; Green, B. D.

In: Current Drug Metabolism, Vol. 10, No. 2, 02.2009, p. 125-137.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis

AU - Flatt, Peter

AU - Bailey, C. J.

AU - Green, B. D.

PY - 2009/2

Y1 - 2009/2

N2 - The enteroinsular axis (EIA) constitutes a physiological signalling system whereby intestinal endocrine cells secrete incretin hormones following feeding that potentiate insulin secretion and contribute to the regulation of blood glucose homeostasis. The two key hormones responsible are named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent years have witnessed sustained development of antidiabetic therapies that exploit the EIA. Current clinical compounds divide neatly into two classes. One concerns analogues or mimetics of GLP-1, such as exenatide (Byetta) or liraglutide (NN2211). The other group comprises the gliptins (e. g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Ongoing research indicates that further incretin and gliptin compounds will become available for clinical use in the near future, offering comparable or improved efficacy. For incretin analogues there is the prospect of prolonged duration of action and alternative routes of administration. This review focuses on recent advances in pre-clinical research and their translation into clinical studies to provide future therapies for type 2 diabetes targeting the EIA.

AB - The enteroinsular axis (EIA) constitutes a physiological signalling system whereby intestinal endocrine cells secrete incretin hormones following feeding that potentiate insulin secretion and contribute to the regulation of blood glucose homeostasis. The two key hormones responsible are named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent years have witnessed sustained development of antidiabetic therapies that exploit the EIA. Current clinical compounds divide neatly into two classes. One concerns analogues or mimetics of GLP-1, such as exenatide (Byetta) or liraglutide (NN2211). The other group comprises the gliptins (e. g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Ongoing research indicates that further incretin and gliptin compounds will become available for clinical use in the near future, offering comparable or improved efficacy. For incretin analogues there is the prospect of prolonged duration of action and alternative routes of administration. This review focuses on recent advances in pre-clinical research and their translation into clinical studies to provide future therapies for type 2 diabetes targeting the EIA.

M3 - Article

VL - 10

SP - 125

EP - 137

JO - Current Drug Metabolism

T2 - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 2

ER -